ADC payload with a differentiated mechanism of action; Combines oncology expertise of Novartis with Myricx Bio’s ...
BEIJING, April 21, 2026 (GLOBE NEWSWIRE)-- At the 2026 American Association for Cancer Research (AACR) Annual Meeting, InnoCare Pharma (HKEX: 9969; SSE: 688428) presented preclinical data of its novel ...
The deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC ...
Novartis is pushing deeper into antibody-drug conjugate (ADC) development, paying $1.1 billion upfront to buy Myricx Bio for a pipeline based on a novel payload. Switzerland’s Novartis largely stayed ...
CHENGDU, China, June 2, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 American Society of Clinical ...
Pharmaceutical Technology on MSN
Novartis to acquire Myricx Bio in up to $1.5bn deal
The acquisition is expected to close in the second half of 2026, pending customary closing conditions and regulatory ...
CAMBRIDGE, United Kingdom and NEW YORK, May 12, 2026 - Artios Pharma Limited ("Artios”), a clinical-stage biopharmaceutical company pioneering the development of new classes of DNA Damage Response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results